RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx, Inc. (RNXT)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai’s presentation will be held on Tuesday, December 9th at 12:30 P.M. ET. Mr. Bagai will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. RenovoRx recently reported third quarter of 2025 financial results, demonstrating progress as year-to-date (end of September 30, 2025) revenue grew to approximately $900,000. He will also discuss recent advancements in the Compa
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx Establishes RenovoCath® Medical Advisory BoardGlobeNewswire
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial OfficerGlobeNewswire
- RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific MeetingGlobeNewswire
- RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.MarketBeat
- RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific MeetingGlobeNewswire
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 2/6/26 - Form 8-K
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- RNXT's page on the SEC website